Pharmacokinetics and pharmacotherapy of thionamides in pregnancy

Therapeutic Drug Monitoring

Volumn 28, Issue 4, 2006, Pages 477-483

  Clark, Shannon M ^a   Saade, George R ^a   Snodgrass, Wayne R ^a   Hankins, Gary D V ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Pharmacokinetics; Pharmacotherapy; Pregnancy; Thioamides

Indexed keywords

ANTIHISTAMINIC AGENT; CARBIMAZOLE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE DERIVATIVE; THYROGLOBULIN; THYROID HORMONE;

AGRANULOCYTOSIS; ANTITHYROID ARTHRITIS SYNDROME; ARTHRALGIA; ARTHRITIS; BREAST MILK; CHOANA ATRESIA; CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; EMBRYOPATHY; ESOPHAGUS ATRESIA; FEVER; GOITER; GRAVES DISEASE; GROWTH RETARDATION; HAIR LOSS; HASHIMOTO DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOASSAY; LIVER CELL DAMAGE; LIVER FAILURE; LIVER TOXICITY; LUPUS LIKE SYNDROME; NAUSEA; PLACENTA; POLYARTHRITIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SKIN APLASIA; SORE THROAT; TERATOGENICITY; THYROID DISEASE; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL; THYROID WEIGHT; TRACHEOESOPHAGEAL FISTULA; UNITED STATES; VASCULITIS;

ANTITHYROID AGENTS; CARBIMAZOLE; FEMALE; HUMANS; HYPERTHYROIDISM; METHIMAZOLE; PREGNANCY; PREGNANCY COMPLICATIONS; PROPYLTHIOURACIL; SULFHYDRYL COMPOUNDS; THIONES;

EID: 33746848143     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200608000-00001     Document Type: Review

References (51)

1. Demers LM. Thyroid disease: pathophysiology and diagnosis. Clin Lab Med. 2004;24:19-28.
2. Bouknight AL. Thyroid physiology and thyroid function testing. Otolaryngol Clin N Am. 2003;36:9-15.
3. Neale D, Burrow G. Thyroid disease in pregnancy. Obstet Gynecol Clin. 2004;31:893-905.
4. Nader S. Thyroid disease and other endocrine disorders in pregnancy. Obstet Gynecol Clin N Am. 2004;31:257-285.
5. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab. 2001;86:2354-2359.
6. Jansson R, Dahlbeg PA, Winsa B. The postpartum period constitutes an important risk for development of clinical Graves' disease in young women. Acta Endocrinol. 1987;116:321-325.
7. McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992;2:155-159.
8. Weetman AP. Graves' disease. N Engl J Med. 2000;343:1236-1248.
9. Momotani N, Noh JY, Ishikawa N, et al. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab. 1997;82:3633-3636.
10. Kung AWC, Chau MT, Lao TT, et al. The effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab. 2002;87:1010-1014.
11. Burrow GN, Fischer DA, Larsen PR. Mechanisms of disease: maternal and fetal thyroid function. N Engl J Med. 1994;331:1072-1078.
12. Yeo CP, Khoo DHC, Eng PHK, et al. Prevalence of gestational thyrotoxicosis in Asian women evaluated in the 8th to 14th weeks of pregnancy: correlations with total and free beta human chorionic gonatropin. Clin Endocrinol (Oxf). 2001;55:391-398.
13. Ferris TF. Renal disease. In: Burrow GN, Ferris TF, eds. Medical Complications During Pregnancy. Philadelphia: WB Saunders; 1988.
14. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905-917.
15. Benker G, Reinwein D. Pharmacokinetics of antithyroid drugs. Klin Wochenschr. 1982;60:531-539.
16. 35S-antithyroid drug concentration and organic binding of iodine in the human thyroid. Clin Endocrinol. 1975;4:609-613.
17. Di Gianantonio E, Schaeffer C, Mastroiacovo PP, et al. Adverse effects of prenatal methimazole exposure. Teratology. 2001;64:262-266.
18. Cooper DS, Bode HH, Nath B, et al. Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for methimazole. J Clin Endocrinol Metab. 1984;58:473-479.
19. Skellern GG, Knight BI, Low CKL, et al. The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole in hyperthyroid patients. Br J Clin Pharmacol. 1980;9:137-143.
20. Jansson R, Lindstrom B, Dahlberg PA. Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet. 1985;10:443-450.
21. Hengstmann JH, Hohn H. Pharmacokinetics of methimazole in humans. Klin Wochenschr. 1985;63:1212-1217.
22. Okamura Y, Shigemasa C, Tatsuhara T. Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients. Endocrinol Japon. 1986;33:605-615.
23. Kampmann JP. Pharmakokinetics of propylthiouracil in man after intravenous infusion. J Pharmacokinet Biopharm. 1977;5:435-443.
24. Kampmann J, Skovsted L. The pharmacokinetics of propylthiouracil. Acta Pharmacol Toxicol. 1974;35:361-369.
25. Barnes HV, Bledsoe T. A simple test for selecting the thionamide schedule in thyrotoxicosis. J Clin Endocrinol Metab. 1972;35:250-255.
26. Cooper DS. Which anti-thyroid drug. Am J Med. 1986;80:1165-1168.
27. Meyer-Gessner M, Benker G, Lederbogen S, et al. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest. 1994;17:29-36.
28. Gardner DF, Cruishank DP, Hays PM, et al. Pharmacology of propylthiouracil (PTU) in pregnant hyperthyroid women: correlation of maternal PTU concentrations with cord serum thyroid function tests. J Clin Endocrinol Metab. 1986;62:217-220.
29. Skellern GG, Knight BI, Otter M, et al. The pharmacokinetics in pregnant patients after oral administration of carbimazole. Br J Clin Pharmacol. 1980;9:145-147.
30. Mortimer RH, Cannell GR, Addison RS, et al. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab. 1997;82:3099-3102.
31. Cooper DS. The side effects of antithyroid drugs. Endocrinologist. 1999;9:457-476.
32. Farwell AP, Braverman LE. Thyroid and antithyroid drugs. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001.
33. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid. 2004;14:459-462.
34. Ruiz JK, Rossi GV, Vallejos HA, et al. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother. 2003;37:224-228.
35. Kim HJ, KIM BH, Han YS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol. 2001;96:165-169.
36. Brusco F, Gonzalez G, Soto N, et al. Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure. Thyroid. 2004;14:862-865.
37. Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab. 1995;80:1083-1085.
38. Wing DA, Millar LK, Koonings PP, et al. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol. 1994;170:90-95.
39. Mestman J. Hyperthyroidism in pregnancy. Baillieres Best Pract Res Clin Endocrinol Metab. 2004;18:267-288.
40. Shahid R. Pregnancy with hyperthyroidism. J Coll Physicians Surg Pak. 2003;13:255-259.
41. Zakarija M, McKenzie JM, Banovac K. Clinical significance of assay of thyroid-stimulating-antibody on Graves' disease. Ann Intern Med. 1980;93:28-32.
42. He CT, Hsieh AT, Pei D, et al. Comparison of single daily dose of methimazole and proylthiouracil in the treatment of Graves' hyperthyroidism. Clin Endocrinol. 2004;60:676-681.
43. Homsanit M, Sriussadaporn S, Nannasaeng S, et al. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol. 2001;54:385-390.
44. Kriplani A, Buckshee K, Bhargava VL, et al. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol. 1994;54:159-163.
45. Kampmann JP, Johansen K, Hansen JM, et al. Propylthiouracil in human milk. Revision of a dogma. Lancet. 1980;1:736-737.
46. Azizi F, Hedayati M. Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J Endocrinol Invest. 2002;25:493-496.
47. Momotani N, Yamashita R, Makino F, et al. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol. 2000;53:177-181.
48. Azizi F, Bahrainian M, Khamseh ME, et al. Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. J Pediatr Endocrinol. 2003;16:1239-1243.
49. Soldin SJ, Soukhova N, Janicic N, et al. A new approach: the measurement of free thyroxine by isotope dilution tandem mass spectrometry. Clin Chim Acta. 2005; 358:113-118.
50. Soldin OP, Hilakivi-Clarke L, Weiderpass E, et al. Trimester-specific reference intervals for thyroxine and triiodothryonine in pregnancy in iodine-sufficient women using isotope dilution tandem mass spectrometry and immunoassays. Clin Chim Acta. 2004;349:181-189.
51. Soldin OP, Tractenberg RE, Soldin SJ. Differences between measurements of T4 and T3 in pregnant and non-pregnant women using isotope dilution tandem mass spectrometry and immunoassays: are there clinical implications? Clin Chim Acta. 2004;347:61-69.